Aveanna Healthcare Holdings Inc. (AVAH) AI Stock Analysis

Aveanna Healthcare Holdings Inc. is a multifaceted home care platform company in the United States. Its patient-centered care delivery model allows individuals to receive care in their homes, reducing hospital stays. It operates through three main segments: Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). PDS provides specialized in-home skilled nursing for medically fragile children, school-based nursing, pediatric day healthcare centers, and therapy services. HHH provides home health nursing, therapy, medical social services, and hospice care. The MS segment supplies enteral nutrition and medical supplies.

Aveanna grew annual revenue from $1.68B in FY2021 to $2.43B in FY2025, representing a 5-year revenue CAGR of 10.2%. Following net losses from FY2021 through FY2024, including a net loss of -$662.0M in FY2022 and -$10.9M in FY2024, the company recorded net income of $225.0M in FY2025 with a net margin of 9.2%. Operating margin also expanded to 10.9% in FY2025, up from 6.9% in FY2024 and -35.9% in FY2022. For the trailing twelve months ended June 30, 2026, revenue stood at $2.60B with a profit margin of 10.6%. In the latest quarter, quarterly revenue grew 13.7% year-over-year while quarterly earnings expanded 38.5%.

As of June 30, 2026, Aveanna held $97.2M in cash and short-term investments against $1.51B in total debt, resulting in net debt of $1.41B. Shareholders' equity was $287.3M, yielding a debt-to-equity ratio of 5.24 and a current ratio of 1.16. In FY2025, the company generated $122.2M in operating cash flow and $114.8M in free cash flow, while capital expenditures totaled $7.4M. Over the last five years, share count increased by 19.5%.

Aveanna trades at a trailing P/E of 9.8x and a forward P/E of 13.3x, compared to the median of its US-listed Healthcare peers of 24.6x and 17.3x, respectively. Its price-to-sales ratio is 1.0x versus the peer median of 4.1x, while its EV/EBITDA multiple is 13.8x compared to the peer median of 12.0x. Over the past year, the stock returned 23.5%, outperforming the S&P 500 (SPY) return of 16.8%. Over a 5-year period, the stock generated a return of 83.4%, compared to 83.0% for the S&P 500.

Wall Street coverage includes 6 Strong Buy, 2 Buy, and 3 Hold ratings, with no Sell or Strong Sell recommendations. The mean price target is $14.85, representing an upside of 20.3% over the last close of $12.34. Aveanna has beaten earnings expectations in each of the last 4 quarters. For the current fiscal year ending December 31, 2026, analysts estimate EPS of $0.82 on revenue of $2.69B. For the following fiscal year, 11 analysts project EPS of $0.91 and revenue of $2.90B. The next earnings date is November 5, 2026.

This page is an AI-written research summary of Aveanna Healthcare Holdings Inc. (AVAH). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: AVAH income statement, AVAH balance sheet, AVAH key metrics, AVAH analyst forecast, AVAH chart. See the AVAH stock overview for the latest quote and news.